Angle Targets March For US FDA De Novo Submission

Following a Q-submission meeting with the US FDA, liquid biopsy firm Angle says it is in a strong position to progress a de novo submission for the Parsortix system by end of Q1.

Cancer cells on scientific background.3d illustration

Liquid biopsy firm Angle PLC says it will progress a de novo US Food & Drug Administration submission for its Parsortix blood test by March.

UK-based Angle is aiming to become the first company to receive clearance from the FDA for a platform that captures...

More from Oncology

More from Device Area